Cargando…

The Cao-Xiang-Wei-Kang formula attenuates the progression of experimental colitis by restoring the homeostasis of the microbiome and suppressing inflammation

Inflammatory bowel disease (IBD) is pathologically characterized by an immune response accommodative insufficiency and dysbiosis accompanied by persistent epithelial barrier dysfunction. The Cao-Xiang-Wei-Kang (CW) formula has been utilized to treat gastrointestinal disorders in the clinic. The pres...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Wei, Li, Qi, Shao, Changlei, Zhang, Yijia, Kang, Cai, Zheng, Yang, Liu, Xihao, Liu, Xincheng, Yan, Jing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9530714/
https://www.ncbi.nlm.nih.gov/pubmed/36204231
http://dx.doi.org/10.3389/fphar.2022.946065
_version_ 1784801745987174400
author Yu, Wei
Li, Qi
Shao, Changlei
Zhang, Yijia
Kang, Cai
Zheng, Yang
Liu, Xihao
Liu, Xincheng
Yan, Jing
author_facet Yu, Wei
Li, Qi
Shao, Changlei
Zhang, Yijia
Kang, Cai
Zheng, Yang
Liu, Xihao
Liu, Xincheng
Yan, Jing
author_sort Yu, Wei
collection PubMed
description Inflammatory bowel disease (IBD) is pathologically characterized by an immune response accommodative insufficiency and dysbiosis accompanied by persistent epithelial barrier dysfunction. The Cao-Xiang-Wei-Kang (CW) formula has been utilized to treat gastrointestinal disorders in the clinic. The present study was designed to delineate the pharmacological mechanisms of this formula from different aspects of the etiology of ulcerative colitis (UC), a major subtype of IBD. Dextran sodium sulfate (DSS) was given to mice for a week at a concentration of 2%, and the CW solution was administered for 3 weeks. 16S rRNA gene sequencing and untargeted metabolomics were conducted to examine the changes in the microbiome profile, and biochemical experiments were performed to confirm the therapeutic functions predicted by system pharmacology analysis. The CW treatment hampered DSS-induced experimental colitis progression, and the targets were enriched in inflammation, infection, and tumorigenesis, which was corroborated by suppressed caspase 3 (Casp3) and interleukin-1b (IL-1b) and increased cleaved caspase 3 expression and casp-3 activity in the colon samples from colitis mice subjected to the CW therapy. Moreover, the CW therapy rescued the decreased richness and diversity, suppressed the potentially pathogenic phenotype of the gut microorganisms, and reversed the altered linoleic acid metabolism and cytochrome P450 activity in murine colitis models. In our in vitro experiments, the CW administration increased the alternative activation of macrophages (Mφs) and inhibited the tumor necrosis factor-α (TNFα)-induced reactive oxygen species (ROS) level and subsequent death in intestinal organoids (IOs). We propose that the CW formula alleviates the progression of murine colitis by suppressing inflammation, promoting mucosal healing, and re-establishing a microbiome profile that favors re-epithelization.
format Online
Article
Text
id pubmed-9530714
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-95307142022-10-05 The Cao-Xiang-Wei-Kang formula attenuates the progression of experimental colitis by restoring the homeostasis of the microbiome and suppressing inflammation Yu, Wei Li, Qi Shao, Changlei Zhang, Yijia Kang, Cai Zheng, Yang Liu, Xihao Liu, Xincheng Yan, Jing Front Pharmacol Pharmacology Inflammatory bowel disease (IBD) is pathologically characterized by an immune response accommodative insufficiency and dysbiosis accompanied by persistent epithelial barrier dysfunction. The Cao-Xiang-Wei-Kang (CW) formula has been utilized to treat gastrointestinal disorders in the clinic. The present study was designed to delineate the pharmacological mechanisms of this formula from different aspects of the etiology of ulcerative colitis (UC), a major subtype of IBD. Dextran sodium sulfate (DSS) was given to mice for a week at a concentration of 2%, and the CW solution was administered for 3 weeks. 16S rRNA gene sequencing and untargeted metabolomics were conducted to examine the changes in the microbiome profile, and biochemical experiments were performed to confirm the therapeutic functions predicted by system pharmacology analysis. The CW treatment hampered DSS-induced experimental colitis progression, and the targets were enriched in inflammation, infection, and tumorigenesis, which was corroborated by suppressed caspase 3 (Casp3) and interleukin-1b (IL-1b) and increased cleaved caspase 3 expression and casp-3 activity in the colon samples from colitis mice subjected to the CW therapy. Moreover, the CW therapy rescued the decreased richness and diversity, suppressed the potentially pathogenic phenotype of the gut microorganisms, and reversed the altered linoleic acid metabolism and cytochrome P450 activity in murine colitis models. In our in vitro experiments, the CW administration increased the alternative activation of macrophages (Mφs) and inhibited the tumor necrosis factor-α (TNFα)-induced reactive oxygen species (ROS) level and subsequent death in intestinal organoids (IOs). We propose that the CW formula alleviates the progression of murine colitis by suppressing inflammation, promoting mucosal healing, and re-establishing a microbiome profile that favors re-epithelization. Frontiers Media S.A. 2022-09-20 /pmc/articles/PMC9530714/ /pubmed/36204231 http://dx.doi.org/10.3389/fphar.2022.946065 Text en Copyright © 2022 Yu, Li, Shao, Zhang, Kang, Zheng, Liu, Liu and Yan. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Yu, Wei
Li, Qi
Shao, Changlei
Zhang, Yijia
Kang, Cai
Zheng, Yang
Liu, Xihao
Liu, Xincheng
Yan, Jing
The Cao-Xiang-Wei-Kang formula attenuates the progression of experimental colitis by restoring the homeostasis of the microbiome and suppressing inflammation
title The Cao-Xiang-Wei-Kang formula attenuates the progression of experimental colitis by restoring the homeostasis of the microbiome and suppressing inflammation
title_full The Cao-Xiang-Wei-Kang formula attenuates the progression of experimental colitis by restoring the homeostasis of the microbiome and suppressing inflammation
title_fullStr The Cao-Xiang-Wei-Kang formula attenuates the progression of experimental colitis by restoring the homeostasis of the microbiome and suppressing inflammation
title_full_unstemmed The Cao-Xiang-Wei-Kang formula attenuates the progression of experimental colitis by restoring the homeostasis of the microbiome and suppressing inflammation
title_short The Cao-Xiang-Wei-Kang formula attenuates the progression of experimental colitis by restoring the homeostasis of the microbiome and suppressing inflammation
title_sort cao-xiang-wei-kang formula attenuates the progression of experimental colitis by restoring the homeostasis of the microbiome and suppressing inflammation
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9530714/
https://www.ncbi.nlm.nih.gov/pubmed/36204231
http://dx.doi.org/10.3389/fphar.2022.946065
work_keys_str_mv AT yuwei thecaoxiangweikangformulaattenuatestheprogressionofexperimentalcolitisbyrestoringthehomeostasisofthemicrobiomeandsuppressinginflammation
AT liqi thecaoxiangweikangformulaattenuatestheprogressionofexperimentalcolitisbyrestoringthehomeostasisofthemicrobiomeandsuppressinginflammation
AT shaochanglei thecaoxiangweikangformulaattenuatestheprogressionofexperimentalcolitisbyrestoringthehomeostasisofthemicrobiomeandsuppressinginflammation
AT zhangyijia thecaoxiangweikangformulaattenuatestheprogressionofexperimentalcolitisbyrestoringthehomeostasisofthemicrobiomeandsuppressinginflammation
AT kangcai thecaoxiangweikangformulaattenuatestheprogressionofexperimentalcolitisbyrestoringthehomeostasisofthemicrobiomeandsuppressinginflammation
AT zhengyang thecaoxiangweikangformulaattenuatestheprogressionofexperimentalcolitisbyrestoringthehomeostasisofthemicrobiomeandsuppressinginflammation
AT liuxihao thecaoxiangweikangformulaattenuatestheprogressionofexperimentalcolitisbyrestoringthehomeostasisofthemicrobiomeandsuppressinginflammation
AT liuxincheng thecaoxiangweikangformulaattenuatestheprogressionofexperimentalcolitisbyrestoringthehomeostasisofthemicrobiomeandsuppressinginflammation
AT yanjing thecaoxiangweikangformulaattenuatestheprogressionofexperimentalcolitisbyrestoringthehomeostasisofthemicrobiomeandsuppressinginflammation
AT yuwei caoxiangweikangformulaattenuatestheprogressionofexperimentalcolitisbyrestoringthehomeostasisofthemicrobiomeandsuppressinginflammation
AT liqi caoxiangweikangformulaattenuatestheprogressionofexperimentalcolitisbyrestoringthehomeostasisofthemicrobiomeandsuppressinginflammation
AT shaochanglei caoxiangweikangformulaattenuatestheprogressionofexperimentalcolitisbyrestoringthehomeostasisofthemicrobiomeandsuppressinginflammation
AT zhangyijia caoxiangweikangformulaattenuatestheprogressionofexperimentalcolitisbyrestoringthehomeostasisofthemicrobiomeandsuppressinginflammation
AT kangcai caoxiangweikangformulaattenuatestheprogressionofexperimentalcolitisbyrestoringthehomeostasisofthemicrobiomeandsuppressinginflammation
AT zhengyang caoxiangweikangformulaattenuatestheprogressionofexperimentalcolitisbyrestoringthehomeostasisofthemicrobiomeandsuppressinginflammation
AT liuxihao caoxiangweikangformulaattenuatestheprogressionofexperimentalcolitisbyrestoringthehomeostasisofthemicrobiomeandsuppressinginflammation
AT liuxincheng caoxiangweikangformulaattenuatestheprogressionofexperimentalcolitisbyrestoringthehomeostasisofthemicrobiomeandsuppressinginflammation
AT yanjing caoxiangweikangformulaattenuatestheprogressionofexperimentalcolitisbyrestoringthehomeostasisofthemicrobiomeandsuppressinginflammation